What is Tikva Allocell?
Based in Singapore, Tikva Allocell operates at the intersection of advanced cellular engineering and therapeutic development. The company is primarily engaged in the creation of off-the-shelf T cell therapies, specifically targeting complex oncological conditions and autoimmune disorders. By utilizing its proprietary Allogeneic EBV-Specific T Cell (ALLO EBVST) platform, Tikva Allocell aims to disrupt the current immunotherapy landscape. The firm's core value proposition lies in its ability to manufacture readily available, affordable, and scalable treatments, effectively addressing the logistical and economic barriers often associated with personalized cell-based medicine. Through its innovative engineering technologies, the company is positioning itself as a key player in the global effort to improve patient outcomes through next-generation biological interventions.
How much funding has Tikva Allocell raised?
Tikva Allocell has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2026): $8M, investors not publicly disclosed
Key Investors in Tikva Allocell
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Tikva Allocell?
With this major strategic investment, Tikva Allocell is well-positioned to scale its preclinical operations and advance its lead candidates toward clinical validation. The company's roadmap likely involves expanding its laboratory infrastructure and strengthening its intellectual property portfolio surrounding the ALLO EBVST platform. Furthermore, the capital will facilitate the recruitment of specialized talent and the establishment of strategic partnerships necessary for navigating the complex regulatory environments of international biotech markets. As the firm moves forward, the focus will remain on demonstrating the safety and efficacy of its off-the-shelf solutions, a milestone that will be essential for securing future growth and long-term commercial viability in the high-stakes immunotherapy market.
See full Tikva Allocell company page
